Identification of a new psychoactive substance in seized material:The synthetic opioid <i>N</i>-phenyl-<i>N</i>-[1-(2-phenethyl)piperidin-4-yl]prop-2-enamide (Acrylfentanyl) by Breindahl, Torben et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Identification of a new psychoactive substance in seized material
Breindahl, Torben; Kimergård, Andreas; Andreasen, Mette Findal; Pedersen, Daniel Sejer
Published in:
Drug Testing and Analysis
DOI:
10.1002/dta.2046
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Breindahl, T., Kimergård, A., Andreasen, M. F., & Pedersen, D. S. (2017). Identification of a new psychoactive
substance in seized material: The synthetic opioid N-phenyl-N-[1-(2-phenethyl)piperidin-4-yl]prop-2-enamide
(Acrylfentanyl). Drug Testing and Analysis, 9(3), 415-422. https://doi.org/10.1002/dta.2046
Download date: 03. Feb. 2020
Identification of a new psychoactive substance
in seized material: the synthetic opioid N-
phenyl-N-[1-(2-phenethyl)piperidin-4-yl]prop-
2-enamide (Acrylfentanyl)
Torben Breindahl,a* Andreas Kimergård,b Mette Findal Andreasenc
and Daniel Sejer Pedersend
Among the new psychoactive substances (NPS) that have recently emerged on the market, many of the new synthetic opioids
have shown to be particularly harmful. A new synthetic analogue of fentanyl, N-phenyl-N-[1-(2-phenethyl)piperidin-4-yl]prop-
2-enamide (acrylfentanyl), was identified in powder from a seized capsule found at a forensic psychiatric ward in Denmark.
Gas chromatography with mass spectrometry (GC-MS) identified a precursor to synthetic fentanyls, N-phenyl-1-(2-phenylethyl)
piperidin-4-amine; however, the precursor 1-(2-phenethyl)piperidin-4-one, was not detected. Analysis of the electron impact
mass spectrum of the main, unknown chromatographic peak (GC) tentatively identified an acryloyl analogue of fentanyl. Further
analyses by quadrupole time-of-flight high resolution mass spectrometry (QTOF-MS), matrix-assisted laser ionization Orbitrap
mass spectrometry (MALDI-Orbitrap-MS), nuclear magnetic resonance spectroscopy (NMR), and infra-red spectroscopy (IR) con-
firmed the presence of acrylfentanyl (also known as acryloylfentanyl). Quantitative analysis with liquid chromatography and tri-
ple quadrupole mass spectrometry (LC-MS/MS) determined the content of acrylfentanyl in the powder, equal to 88.3 mass-%
acrylfentanyl hydrochloride. An impurity observed by NMR was identified as triethylamine hydrochloride. Acrylfentanyl is sold
on the Internet as a ‘research chemical’. Like other synthetic fentanyls, such as acetylfentanyl, it poses a serious risk of fatal
intoxication. Copyright © 2016 The Authors. Drug Testing and Analysis Published by John Wiley & Sons Ltd.
Additional supporting information may be found in the online version of this article at the publisher’s web site.
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Introduction
The rapid appearance of new psychoactive substances (NPS) that
are not controlled under international and national drug laws pres-
ent a serious problem for public health. This drug phenomenon is
characterised by the high number of new substances emerging
each year, which in Europe meant a continuous increase in the
number of new substances recorded for the first time from 24 in
2009 to 98 in 2015.[1,2] Constantly changing, the transformation of
the market is different from anything recorded historically,[3] and
has led to a global spread of new psychoactive substances.[4]
New synthetic opioids pose an especially serious concern for
public health because of their high potency and because they are
often sold under the guise of heroin to unsuspecting users.[5–7] Of
particular note is illicitly manufactured fentanyl and its derivatives
that have been involved in hundreds of deaths worldwide. Since
the first appearance on themarket in the USA in the late 1970s, sold
as ‘synthetic heroin’ and ‘ChinaWhite’,[8–10] fentanyls have been de-
tected in Europe, Canada, Australia, Japan, and elsewhere, resulting
in overdoses and outbreaks of deaths. Estonia faces a serious situa-
tion with hundreds of deaths involving use of illicitly produced
fentanyls, accompanied by a growth in the number of seizures,
overdoses, and treatment demand.[11,12] In 2015, 32 deaths re-
ported in Germany, Poland, Sweden, and the UK related to
acetylfentanyl.[13] The proportion of illicit drug overdose deaths in-
volving fentanyls has grown in Canada during the last few years to
exceed 50% in some parts of the country.[14–16] Since 2012, 12
deaths in Russia[17] and more than 50 deaths in the USA have been
associated with acetylfentanyl.[18–22] Other fentanyl analogues,
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such as butyrfentanyl, 3-methylfentanyl, and furanylfentanyl, have
also been linked to serious adverse events.[23–25] Additional risks
arise from hazardous injecting behaviours, such as injecting
fentanyls with used needles and syringes that can cause the spread
of hepatitis C and HIV.[12]
Synthetic cannabinoids are currently the largest group of NPS
monitored by the European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA), followed by synthetic cathinones.[1]
Since 2008, 160 synthetic cannabinoids have been detected in
Europe; 103 synthetic cathinones have been recorded from
2004 onwards. The number of new opioids recorded since 2009
is much lower in comparison (less than 20)[1] with several of these
being highly potent fentanyls.[1,2] However, whilst these drugs
appear to take up a small proportion of the market, they can
be particularly harmful.
The use of fentanyls presents a complicated problem character-
ized by: (1) diversion from patients, tampering, and misuse of
licensed medicines containing fentanyl (used as an analgesic
drug); (2) availability of illicit fentanyl; (3) the emergence of a range
of new fentanyl derivatives, sold illicitly as ‘research chemicals’,
which may avoid detection by regulating authorities for long
periods of time; (4) the availability of fentanyl and derivatives on
the Internet and the dark net, which is one of the key drivers of
the global spread of new psychoactive substances; (5) increasing
use of fentanyls that are far more potent as an analgesic than mor-
phine; (6) fentanyls sold in highly concentrated powder form
where it is difficult to estimate strength and manage the dose,
posing a serious risk of overdose; and (7) complex marketing,
including fentanyls passed off as heroin[6,7,26] and heroin as
fentanyl,[27] fentanyl mixed with cocaine, heroin, amphetamine,
and other NPS such as U-47700 (a synthetic opioid),[28,29] and fake
medicines sold on the illicit market (e.g. Xanas and oxycodone)
laced with fentanyl.[5,28] All of this relates to the supply and use
of heroin and may contribute to the recent increase in overall
estimates of opioid deaths in Europe.
In this dynamic market place, keeping upwith manufactures and
suppliers of NPS is essential and yet detecting new drugs on the
market, including fentanyl analogues, is very challenging in both
clinical settings and in post-mortem forensic analysis. Fentanyl
derivatives may escape detection because routine testing of these
drugs is rarely performed. In this study we report the identification
of the fentanyl analogue acrylfentanyl (also known as
acryloylfentanyl) in a seized sample obtained from a psychiatric
ward at a Danish hospital. To the best of our knowledge this is
the first analytically confirmed non-biological case published within
Europe.
Materials
A capsule was seized in May 2016 during a smuggling attempt at
the Forensic Psychiatric Department at Aalborg Psychiatric Hospital
(Denmark). The sample consisted of a white to pale-yellow powder
inside a translucent capsule (Figure 1). Initially, a large part of the
powder was used by the staff to prepare an ad hoc aqueous solu-
tion, to test with an immunoassay panel, ABC-multi-10 (Simoco Di-
agnostics, Hillerød, Denmark). This indicated a positive reaction for
3,4-methylenedioxymethamphetamine (MDMA). Subsequently, the
capsule and the remaining powder (less than 6mg) was sent to the
Department of Clinical Biochemistry, North Denmark Regional Hos-
pital (Denmark), for further analysis.
The standard of fentanyl used as reference was from Cerilliant
(Round Rock, TX, USA). The standard of acrylfentanyl hydrochloride
(CAS no. 79279-03-1) was from Cayman Chemical (Ann Arbor, MI,
USA). The standard of N-phenyl-1-(2-phenylethyl)piperidin-4-amine
was from Carbosynth (Compton, Berkshire, UK).
Methods
Gas chromatography-mass spectrometry (GC-MS)
Analysis was performed at the Department of Clinical Biochemistry,
North Denmark Regional Hospital, on a 6890 gas chromatograph
with a 5973 mass spectrometer (GC-MS) from Agilent (Santa Clara,
CA, USA) equipped with a Combi-Pal auto sampler from CTC
(Zwingen, Switzerland). Analysis was performed using a XTI-5 capil-
lary column from Restek (Bellefonte, PA, USA), 30m, 0.25mm i.d.,
film thickness 0.25μm. The injection port temperature was 250 °C,
the transfer line temperature was 280 °C and theMS source temper-
ature was 230 °C. The initial column oven temperature was set to
50 °C and held constant for 1min during injection. The oven tem-
perature was ramped at 25 °C/min to 170 °C. Then the temperature
was ramped at 15 °C/min to 300 °C, where it was held constant for
10min. The carrier gas was helium at a constant flow rate of
1.3mL/min. The sample powder was dissolved in methanol from
Merck (Darmstadt, Germany). The injection volume was 1μL in
splitless mode (1min).
The mass spectrometer was operated in positive full scan mode,
with acquisition of electron impact (EI) mass spectra in the range
m/z 20–550, and the threshold was 100. Data acquisition started
at 4min. Data were processed using MSD Chemstation (02.02) soft-
ware. Mass spectral libraries searches were performed using: (1)
NIST/EPA/NIH library 11 (2011); (2) Mass Spectral Library of Drugs,
Poisons, pesticides, Pollutants and their Metabolites 2011
(MPW2011); and (3) SWGDRUG MS Library version 2.4 (2015).
Nuclear magnetic resonance (NMR) spectroscopy
Analysis by 1D and 2D NMR was performed at the Department of
Drug Design and Pharmacology, University of Copenhagen. NMR
spectra were recorded in CD3OD (CAS # 811-98-3), DMSO-d6 (CAS
# 2206-27-1) (VWR Chemicals, Leuven, Belgium) or CDCl3 (CAS #
865-49-6) (Cambridge Isotope Laboratories, Andover, MA, USA) on
a 400 or 600MHz Bruker instrument (Bremen, Germany).
Triethylamine hydrochloride (CAS # 554-68-7) was from Fluka
Figure 1. Seized capsule containing acrylfentanyl. The ruler shows cm.
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(Sigma-Aldrich, Steinheim, Germany). The obtained FID-files (Free
induction decay) were processed with MestReNova 10 software
using Whittaker smoother baseline correction and exponential
apodization. Signals are reported in ppm (δ) using the solvent as
reference. Coupling constants (J) are given in hertz (Hz). Coupling
constants are rounded to the nearest 0.5Hz. Multiplet patterns
are designated the following abbreviations, or combinations
thereof: m – multiplet, d – doublet, t – triplet, q – quartet. Signal as-
signments were made from unambiguous chemical shifts and
COSY (Correlation spectroscopy), HSQC (Heteronuclear single quan-
tum coherence), and DEPT (Distortionless enhancement by polari-
zation transfer) spectroscopy experiments.
Infra-red (IR) spectroscopy
Infra-red (IR) spectroscopy was recorded on a Spectrum One IR
spectrometer from Perkin-Elmer (Waltham, MA, USA) using Spec-
trumOne version 3.02 software. Samples were loaded as neat solids
and signals (νmax) are reported in wavenumbers (cm
-1) in the range
3600-600 cm-1.
Orbitrap mass spectrometry
Accurate mass measurement was performed by matrix-assisted
laser ionization Orbitrap mass spectrometry (MALDI/Orbitrap MS)
at the Department of Pharmacy, University of Copenhagen. Analy-
sis was performed in positive ion mode with MALDI ionization on
a ThermoQExactive Orbitrapmass spectrometer (Thermo Scientific,
Bremen, Germany) equipped with an AP-SMALDI 10 ion source
(TransmitMIT, Giessen, Germany) and operated with mass resolving
power 140 000 at m/z 200. 2,5-Dihydroxybenzoic acid (CAS # 490-
79-9) (Sigma-Aldrich, Steinheim, Germany) was used as matrix
and lock-mass for internal mass calibration, providing a mass accu-
racy of 3 ppm or better. Samples were dissolved in a solution of
2,5-dihydroxybenzoic acid in methanol (2mg/mL) and 3μL of the
solution was loaded on a glass plate for analysis.
Quadrupole time-of-flight (QTOF)-mass spectrometry
High resolution product ion spectra were acquiredwith quadrupole
time-of-flight mass spectrometry (QTOF-MS) at the Section for Fo-
rensic Chemistry, Aarhus University, using a maXis Impact QTOF
from Bruker Daltonics (Bremen, Germany), equipped with an or-
thogonal electrospray ionization (ESI) source. The software used
to acquire HR-TOF-MS data and instrument control was
OTOFcontrol 3.2 (Bruker Daltonics, Bremen, Germany) and HyStar
3.2 (Bruker Daltonics, Bremen, Germany). Samples were introduced
into the mass spectrometer using an ultra-performance liquid chro-
matography (UPLC) method described by Telving et al.[30] Mass
spectrometry was performed in positive electrospray ionization
mode using Broad Band Collision Induced Dissociation (bbCID).
The mass range was m/z 50 to 1000. Nebulizer gas pressure was
4.0bar, drying gas was set to 11 L/min at a temperature of 220 °C.
Nitrogen was used for nebulizer, drying gas and collision gas. The
mass spectrometer conditions were as follows: capillary voltage of
the ion source, 4.0 kV; end plate offset, 500 V; Funnel 1 RF, 200
Vpp; Funnel 2 RF, 200 Vpp; isCID, 0.0 eV; Hexapole RF, 50 Vpp; Quad-
rupole Ion Energy, 4.0 eV; Quadrupole Low Mass, 50m/z; Collision
Energy, 4.0 eV; Pre Pulse Storage 6.0μs. The spectra rate was set
to 10Hz. Stepping was enabled with the following settings: Mode,
basic; Collision RF from 300 to 700 Vpp; Transfer Time from 30 to
70μs. Analyte fragmentation was performed in bbCID mode with
the settings described, except for the following MS/MS settings:
Collision Energy MS, 4.0 eV and MS/MS 25eV. The instrument
was calibrated externally before each sequence with a 1mM so-
dium formate/acetate solution. Thirty-five clusters (Na(HCOONa)x,
Na(CH3COONa)x and Na(COOHNa)x(COONa)x) were selected and
used for the instrument calibration. Mass range of the chosen clus-
ters was from 90.9766 to 948.8727Da. For post-run mass
calibration and processing of the data the software DataAnalysis
4.1 and Target Analysis 1.3 (Bruker Daltonics, Bremen, Germany)
were used.
Liquid chromatography and triple quadrupole mass spec-
trometry (LC-MS/MS)
The amount of acrylfentanyl in the seized sample was quantified
with high performance liquid chromatography and triple quadru-
pole mass spectrometry (LC-MS/MS) at the Department of Clinical
Biochemistry (North Denmark Regional Hospital). Parameters for
dynamic multiple reaction monitoring (dMRM) were optimized by
flow injection analysis using a standard of acrylfentanyl, and finally
added to an existing routine LC-MS/MS method for drugs-of-abuse
(Table S1). As deuterated internal standard fentanyl-d5 was used.
The parameters for sample preparation, data acquisition and quan-
tification are shown in the Supporting Information.
Results and discussion
GC-MS analysis
Analysis by GC-MS showed a chromatogram (Figure 2) with a major
peak at retention time (RT) 17.949min. The EI mass spectrum
(Figure 3B) could not be identified by library searches. A peak at RT
15.476min was identified as N-phenyl-1-(2-phenylethyl)piperidin-
4-amine, also called 4-anilino-N-phenethylpiperidine with abbrevi-
ation ANPP (A, Figure 4), by both the NIST11 and SWGDRUG MS
library. ANPP is a precursor for illicit synthesis of fentanyl accord-
ing to a method referred to as the ‘Siegfried method’ on the drug
forum discussion forum Erowid.org[31] and a controlled substance
in the United States. However, the synthetic precursor to ANPP,
1-(2-phenethyl)piperidin-4-one (also calledN-phenethyl-piperidone
with abbreviation NPP), was not identified through library searches
or from extracted ion chromatograms of the base peakm/z 112 af-
ter injection of a 2mg/mL sample concentration. Minor peaks in the
chromatogram (Figure 2) included impurities, which were also
present in a blank solvent sample.
The presence of ANPP suggested that the unknown compound
at RT 17.949min could be a fentanyl analogue with a modification
on the exocyclic amine (substitution of the propanoyl group in fen-
tanyl with another moiety). A study by Ohta et al. on GC-MS analysis
of fentanyl and its analogues found two important mass spectro-
metric characteristics for EI spectra: (1) an absence ofmolecular ions
for most fentanyl analogues; and (2) diagnostic ions formed by loss
of a tropylium ion (M-91), which in most cases formed the base
peaks of the mass spectra.[32]
The base peak in the EI mass spectrum of RT 17.949min was m/z
243 (Figure 3). This theoretically corresponds to a molecular ion of
m/z 334 (243+91). Accordingly, the difference in molecular mass be-
tween fentanyl and the unknown compound was determined to
2Da. This could be explained by introduction of a double bond in fen-
tanyl (B, Figure 4) to give an α,β-unsaturated fentanyl analogue (C,
Figure 4). The mass spectrum of the unknown compound is remark-
ably similar to themass spectrum of fentanyl (Figure 3A), acquired on
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the same apparatus. Based on the GC-MS data alone, we arrived at
the hypothesis, that the unknown compound was the acryloyl deriv-
ative of fentanyl (acrylfentanyl). Following the EI fragmentation pat-
terns for fentanyl and related compounds published by Ohta
et al.,[32] the bond cleavage points can be assigned (Figure 3). Three
fragment ions for acrylfentanyl (Figure 3B) differ with 2Da from those
of fentanyl (Figure 3A):m/z 243 (base peak),m/z 200 (from the piper-
idine ring), and m/z 55 (from the acryloyl group).
A new standard, the hydrochloride salt of acrylfentanyl with CAS
# 79279-03-1, was acquired from Cayman Chemical (Ann Arbor, MI,
USA). GC-MS analysis confirmed the RT and EI mass spectrum of
acrylfentanyl in the seized powder. The IUPACnameof acrylfentanyl
(as free base) is N-phenyl-N-[1-(2-phenethyl)piperidin-4-yl]prop-2-
enamide with CAS # 82003-75-6.
A standard of N-phenyl-1-(2-phenylethyl)piperidin-4-amine from
Carbosynth (Compton, Berkshire, UK) was used to confirm RT and EI
mass spectrum of the detected ANPP in the sample. Acrylfentanyl
can be synthesized by a reaction of acryloyl chloride (2-propenoyl
chloride) with ANPP. The acylation of ANPP to synthesise fentanyl
and its analogues is well described and results in high yields (typi-
cally >94%).[33]
Pyrolytic degradation of fentanyl to ANPP during GC analysis is
possible at high injection port temperatures. In a study of pyrolytic
products from fentanyl, using a probe temperature of 750 °C under
anaerobic conditions, minor signals from ANPP could be detected
(1.9 area% of largest chromatographic peak).[34] To test for pyrolytic
degradation with the GC-MS methods applied in the present study
(injection port temperature 250 °C), standards of both fentanyl and
acrylfentanyl (100μg/mL) were injected. However, no ANPP could
be detected. It should be noted that one of the major human
metabolites of fentanyl is ANPP, in this context known as
despropionylfentanyl, hence detection of this compound in
biological matrices does not indicate a specific synthetic pathway.
Fentanyl and acrylfentanyl can be fully baseline separated by GC
analysis using the methods described above with RT 17.653min for
fentanyl and RT 17.839min for acrylfentanyl.
The chemical structures and IUPAC names of fentanyl,
acrylfentanyl and ANPP are depicted in Figure 4.
Analysis by NMR and IR spectroscopy
The seized sample of acrylfentanyl was analysed by 1H- and 13C-
NMR and signals were assigned based on COSY, HSQC and DEPT
spectroscopy experiments. In addition, standards of fentanyl and
acrylfentanyl hydrochloride were analysed by 1H-NMR and com-
pared to that of the seized sample (Supporting Information). Based
on the recorded NMR data, the seized compound was unambigu-
ously identified as acrylfentanyl. Peaks arising from the terminal al-
kene are clearly observed by 1H NMR (Figure 5). The 1H and 13C
NMR spectra are identical to that of the standard (Figures S6–S9)
with the exception of an impurity in the seized sample that was
identified as triethylamine hydrochloride.
In addition to acrylfentanyl (major component) the seized sam-
ple contained an aliphatic impurity that could not be identified
when recorded in CD3OD (400MHz) due to overlapping
1H-NMR
signals with those of acrylfentanyl. At 400MHz in CD3OD a triplet
could be observed at 1.37 ppm, which couples to an overlapping
signal (COSY) at ~3.26 ppm (Figure S2). Most likely the triplet repre-
sents a CH3-group coupling to a CH2-group connected to an elec-
tronegative group. To identify the unknown entity a series of
NMR experiments were performed in DMSO-d6 and CDCl3
(600MHz instrument) in the hope that signal separation of
acrylfentanyl and the unknown compound might be achieved.
When the spectrumwas recorded in CDCl3 there was no useful sep-
aration of the signals, however a broad singlet integrating for one
proton at 12.75ppm (Figure S6) indicated that the compound
was an ammonium ion, most probable the hydrochloride salt as de-
scribed in the Siegfried method. Of note is that another smaller
peak from an ammonium ion was observed at 12.87 ppm suggest-
ing that the unknown compound might also be a hydrochloride
salt. When the spectrum was recorded in DMSO-d6 separation of
the overlapping peaks was achieved (Figure S10). With full separa-
tion of the peaks we determined that the impurity was
triethylamine hydrochloride (TEA×HCl). This was confirmed by re-
cording the 13C-NMR spectrum of a standard of TEA×HCl in
DMSO-d6 and comparing the spectrum to that of the seized sample
(Figure S11). Furthermore, the 1H-NMR sample of the seized
Figure 2. Total ion chromatogram from GC-MS analysis of the seized sample powder, dissolved in methanol (0.2mg/mL), showing (A) N-phenyl-1-(2-
phenylethyl)piperidin-4-amine (precursor for synthesis of fentanyl analogues) at RT 15.576min; and (B) the unknown compound at RT 17.949min,
identified as N-phenyl-N-[1-(2-phenethyl)piperidin-4-yl]prop-2-enamide (synonym: acrylfentanyl). The peak at RT 13.412min is also present in a blank
solvent sample.
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powder of acrylfentanyl in DMSO-d6 was spiked with a standard of
TEA×HCl to unambiguously establish the identity of the impurity
(Figure S12). Based on integration of the triplet arising from
TEA×HCl at 1.19 ppm and the peak at 1.65 ppm arising from
acrylfentanyl (Figure S12A), an acrylfentanyl to TEA×HCl ratio of
1:0.37 was determined. Provided that there are no significant impu-
rities that cannot be detected by 1H-NMR this translates to approx-
imately 14 mass% of TEA×HCl in the seized sample.
The IR spectra of the seized and commercially acquired samples
were recorded on the neat solids. Both samples clearly show the
presence of an ammonium ion at ~2400-2600 cm-1 (Figures S13
and S14).
The presence of TEA×HCl in the seized sample most likely
arises from a modification of the Siegfried method by utilising
triethylamine as the base for the acetylation reaction instead of
pyridine. In the last step of the Siegfried method the hydrochlo-
ride salt of fentanyl is generated. During the equivalent step in
the synthesis of acrylfentanyl we hypothesise that the undesired
Figure 4. Chemical structures. A) N-phenyl-1-(2-phenylethyl)piperidin-4-
amine (synthetic precursor); B) N-phenyl-N-[1-(2-phenethyl)piperidin-4-yl]
propanamide (Fentanyl); C) N-phenyl-N-[1-(2- phenethyl)piperidin-4-yl]
prop-2-enamide (synonym: acrylfentanyl).
Figure 3. Electron impact (EI) mass spectra acquired during GC-MS analysis of (A) a standard of N-phenyl-N-[1-(2-phenethyl)piperidin-4-yl]propanamide
(fentanyl) at RT 17.949min; and (B) the unknown compound, identified as N-phenyl-N-[1-(2-phenethyl)piperidin-4-yl]prop-2-enamide (acrylfentanyl) at RT
17.696min. Background ions were subtracted for both spectra. Bond cleavage sites for key fragment ions are assigned according to Ohta et al.[32]
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TEA×HCl residue was generated in the final product. According
to the Siegfried synthesis lactose is recommended as the dilution
agent but no lactose or other dilution agents were observed by
NMR or IR.
MALDI/Orbitrap MS
Accurate mass measurement by MALDI/Orbitrap MS found m/z
335.2114 for the protonated ion of the unknown compound [M
+H]+ (Figure S3). This matches with the theoretical value for
acrylfentanyl (m/z 335.2118 for C22H27N2O
+) within 1.1ppm.
Product ion spectra (QTOF-MS)
High resolution precursor and product ion spectrum of fentanyl
(C22H28N2O), acquired with quadrupole time-of-flight mass (QTOF),
are shown in Figure 6. The major fragment was m/z 188.1448.
Figure 7 shows the precursor and product ion spectrum for
acrylfentanyl (C22H26N2O). A major fragment with m/z 188.1437
was found. In silico fragmentation of acrylfentanyl using the soft-
ware ACD/MS Fragmenter (Advanced Chemistry Development,
Toronto, Canada) shows a fragment with m/z 188.1434 with the
proposed formula C13H18N. According to a study by Thevis et al.
Figure 5. 1H-NMR spectrum of acrylfentanyl (CD3OD, 400MHz). Enlargement of the region where signals arising from the terminal alkene are observed. See
supporting information for the complete 1H- and 13C-NMR spectra for acrylfentanyl and 1H-NMR data for fentanyl.
Figure 6. Mass spectrum for precursor (+MS) (top) and product ions (+bbCID) (bottom) for fentanyl, (C22H29N2O). The product ion at m/z 188.1448
corresponds to C13H18N, which is a well-known fragmentation pathway for fentanyl (cf.
[35]).
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on analysis of fentanyl this fragmentation is a charge-driven elimi-
nation of N-phenyl-propionimidic acid (M-149).[35]
Quantitative analysis (LC-MS/MS)
Analysis by LC-MS/MS determined the amount of acrylfentanyl
(free base) in the seized powder, equal to 88.3 mass% of
acrylfentanyl hydrochloride. This is in acceptable agreement with
the impurity estimate from NMR spectroscopy (14 mass%).
The use of LC-MS/MS with multiple reaction monitoring (MRM) is
complicated due to the co-elution of fentanyl (RT 5.102min) and
acrylfentanyl (RT 5.103min). Within the resolution limits of a triple
quadrupole mass spectrometer acrylfentanyl may cause interfer-
ence with the detection of fentanyl due to the [M+H]+ + 2 isotope
signals. The metabolites expected after human metabolism,
norfentanyl and noracrylfentanyl, can also be difficult to separate
by liquid chromatography, and hence necessitate the use of high-
resolution mass spectrometry if both compounds are present in
the sample.
Previous studies
Compounds equal in molecular structure to acrylfentanyl have
previously been reported in the literature for opiate receptor
affinity after synthesis,[36] as a theoretical derivative in mathematic
modelling for drug design,[37] and for in vivo activity in mice after
custom synthesis.[38] In the latter study, with the use of mouse
hot plate tests, it was shown that acrylfentanyl was more potent
than fentanyl and had a longer duration of action. A study by Zhu
et al. on the synthesis and analgesic activity of 22 derivatives of
fentanyl, including acrylfentanyl, is only available in Chinese.[39]
No clinical study data are available for the pharmacokinetic and
pharmacodynamic properties of acrylfentanyl in humans.
Immunoassay screening
An aqueous solution of the seized powder (20 000ng/mL) was
tested with the immunoassay drug test described herein. All test
results were negative. When the powder was tested on-site after
the seizure, and a positive result forMDMAwas displayed, the aque-
ous solution may have been saturated, not free from particles or
otherwise incompatible with requirements of the urine testing de-
vice. Although some immunoassays for fentanyl may cross-react
with acrylfentanyl (and prove useful), only a limited number of fen-
tanyl assays have been critically validated for clinical use,[40] hence
screening with LC-MS/MS or equivalent techniques are
recommendable.
Conclusion
The new synthetic analogue (acrylfentanyl) of the potent opioid
fentanyl was detected in a seized sample (powder) in Denmark.
New synthetic opioids present a serious problem for public health
due to their potency and risk of a fatal intoxication. Users of new
synthetic opioids introduced to the illicit market have no certain
knowledge about the presence of contaminants or cutting agents,
which poses an additional risk to the opioid effect of the drug.
Fentanyls can be absorbed through the skin and inhaled, introduc-
ing additional risks to individuals who come in contact with these
drugs, such as package handlers and couriers who encounter
fentanyls ordered online, family and friends of users, where these
drugs are stored in peoples’ homes, law enforcement personnel
and healthcare professionals in hospitals and drug treatment
services. Our findings suggest that testing should be carried out
for acrylfentanyl to monitor its emergence in samples presented
by individual users and in post-mortem forensic analysis under cir-
cumstances suggesting intoxication by an opioid. This could possi-
bly prevent a spike in deaths as previously seen with acetylfentanyl.
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